The comprehensive array of studies discussed in this review encompass the principal targeting approaches employing antibodies and peptides explored over the past decade, displaying promising outcomes and potential advancements in diagnosis and therapy of HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.